Gene

NTRK2

neurotrophic receptor tyrosine kinase 2

Explore in graph →CI-GENE-00017360HGNC:8032 ENSG00000148053 NCBI 4915 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (32)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–32 of 32 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NTRK2 Fusion1
Entrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted

Cohorts

Alteration frequency by cohort (90)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved90 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Cutaneous Squamous Cell Carcinoma (DFCI, Clin Cancer Res 2015) cscc_dfarber_2015	Skin Squamous Cell Carcinoma	Ssm

Literature

Linked publications (17)

25 per page, newest first.

pubmedPublishedShowing 1–17 of 17 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
· Lancet Oncol · 2020 · PMID 31838007 · validated civic_curation pubmed
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
· Lancet Oncol · 2018 · PMID 29606586 · validated civic_curation pubmed
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
· Cancer Discov · 2017 · PMID 28183697 · validated civic_curation pubmed
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
· Lancet Oncol · 2020 · PMID 32105622

NTRK2 Fusion2
Entrectinib	Ganglioglioma	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID12053 In the STARTRK-NG (NCT02650401) phase 1/2 trial, a 10 year old patient with prior chemotherapy treatment who had Ganglioglioma in the Spine, with a tumor category of low grade glioma, and WHO histolog… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC	civic
〃	Brain GlioblastomaALIAS	Predictive	C	Supports Sensitivity Response	1	accepted	EID12035 A 67-year-old male with a diagnosis of Glioblastoma multiforme (GBM), IDH-wildtype, WHO grade 4 underwent a craniotomy with gross total resection. A BCR::NTRK2 fusion (ex1::ex17) was detected by compr… (full text at CIViC) PMID 35673607 · Grogan et al., 2022 · Open in CIViC	civic

NTRK2 Fusion2

Entrectinib

Ganglioglioma

Predictive

Does Not Support Sensitivity Response

accepted

EID12053

In the STARTRK-NG (NCT02650401) phase 1/2 trial, a 10 year old patient with prior chemotherapy treatment who had Ganglioglioma in the Spine, with a tumor category of low grade glioma, and WHO histolog… (full text at CIViC)

PMID 35395680 · Desai et al., 2022 · Open in CIViC

NTRK2 Fusion6
(diagnostic)	Pilocytic Astrocytoma	Diagnostic	C	Supports Positive	2	accepted	EID8653 A case report showing a two-year-old girl with an unusual pilocytic astrocytoma (PA) with both classic- and anaplastic- appearing tumors. A custom NGS panel identified a novel KANK1-NTRK2 fusion in bo… (full text at CIViC) PMID 29804288 · López et al., 2019 · Open in CIViC	civic
(oncogenic)	Sarcoma	Oncogenic	C	Supports Oncogenicity	2	accepted	EID10362 In a further investigation of non-traditional sarcoma cases, a 41-year-old man was thought to have a malignant peripheral nerve sheath tumor (MPNST) in the neck and spinal cord, but large rhabdoid/epi… (full text at CIViC) PMID 34464935 · Chen et al., 2021 · Open in CIViC	civic
〃	Brain GlioblastomaALIAS	Oncogenic	C	Supports Oncogenicity	1	accepted	EID10896 From a retrospective review of 38,095 tumor samples from 33,997 patients that underwent fusion screening at Memorial Sloan Kettering Cancer Center, 87 tumors were found to be positive for an NTRK1, NT… (full text at CIViC) PMID 31375766 · Solomon et al., 2020 · Open in CIViC	civic
Entrectinib	Ganglioneuroblastoma	Predictive	C	Supports Sensitivity Response	1	accepted	EID11854 In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included one patient (7 yo) with … (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC	civic
Larotrectinib	Anaplastic Ependymoma	Predictive	C	Supports Sensitivity Response	4	accepted	EID10360 An MRI in a previously healthy 6-year-old boy now presenting with neurologic abnormalities and seizures revealed a mass obstructing the foramen of Monro and diffuse leptomeningeal dissemination. The p… (full text at CIViC) PMID 34651095 · Mangum et al., 2021 · Open in CIViC	civic
〃	GlioblastomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID10361 An MRI of 26-year-old man presenting with motor weakness and language difficultly revealed a lesion in the left frontal lobe that extended across the corpus callosum. Histologic analysis of the biopsy… (full text at CIViC) PMID 34041811 · Shepherd et al., 2021 · Open in CIViC	civic

NTRK2 A203T2
(oncogenic)	Primary MyelofibrosisALIAS	Oncogenic	C	Supports Oncogenicity	3	submitted	EID8619 In this study deep sequencing was performed on 185 patients with hematological malignancies, and the NTRK2 A203T substitution was detected in one case of primary myelofibrosis. The substitution is loc… (full text at CIViC) PMID 32315394 · Joshi et al., 2020 · Open in CIViC	civic
Entrectinib + LarotrectinibSubstitutes	Primary MyelofibrosisALIAS	Predictive	D	Supports Sensitivity Response	3	submitted	EID8620 Deep sequencing of samples from 185 patients with different hematological malignancies detected an NTRK2 A203T substitution in one case of primary myelofibrosis. When stably expressed into murine inte… (full text at CIViC) PMID 32315394 · Joshi et al., 2020 · Open in CIViC	civic

NTRK2 R458G3
(oncogenic)	Atypical Chronic Myeloid LeukemiaALIAS	Oncogenic	C	Supports Oncogenicity	3	submitted	EID8610 This variant was found in one case of atypical CML out of 185 hematological malignancies. The authors propose that NTRK2 R458G, residing in the juxtamembrane domain, activates TrkB via noncanonical me… (full text at CIViC) PMID 32315394 · Joshi et al., 2020 · Open in CIViC	civic
Crizotinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Supports Sensitivity Response	3	submitted	EID8609 The authors propose that NTRK2 R458G, residing in the juxtamembrane domain, activates TrkB via noncanonical mechanisms that may involve altered interactions between the mutant receptor and lipids in t… (full text at CIViC) PMID 32315394 · Joshi et al., 2020 · Open in CIViC	civic
Entrectinib + LarotrectinibSubstitutes	Atypical Chronic Myeloid LeukemiaALIAS	Predictive	C	Supports Sensitivity Response	2	submitted	EID8625 This variant was found in one case of atypical CML out of 185 hematological malignancies. The authors propose that NTRK2 R458G, residing in the juxtamembrane domain, activates TrkB via noncanonical me… (full text at CIViC) PMID 32315394 · Joshi et al., 2020 · Open in CIViC	civic

NTRK2 Fusion5
(oncogenic)	Low Grade Glioma	Oncogenic	C	Supports Oncogenicity	1	accepted	EID11437 From a retrospective review of 38,095 tumor samples from 33,997 patients that underwent fusion screening at Memorial Sloan Kettering Cancer Center, 87 tumors were found to be positive for an NTRK1, NT… (full text at CIViC) PMID 31375766 · Solomon et al., 2020 · Open in CIViC	civic
〃	Polymorphous Low Grade Neuroepithelial Tumor of the Young	Oncogenic	C	Supports Oncogenicity	1	accepted	EID11438 Molecular profiling of 13 patients with polymorphous low-grade neuroepithelial tumor of the young (PLNTY) at Mayo Clinic, identified 1 patient (15 yo female) with a QKI::NTRK2 (e6::e15) fusion. PMID 34363682 · Ida et al., 2021 · Open in CIViC	civic
〃	Pilocytic Astrocytoma	Oncogenic	C	Supports Oncogenicity	1	accepted	EID11449 Whole genome sequencing of 96 pilocytic astrocytomas by the International Cancer Genome Consortium (ICGC) PedBrain Tumor Project identified QKI::NTRK2 (e6::e16) fusions in 2 cases (5 yo & 12 yo males)… (full text at CIViC) PMID 23817572 · Jones et al., 2013 · Open in CIViC	civic
〃	Anaplastic AstrocytomaALIAS	Oncogenic	D	Supports Oncogenicity	3	accepted	EID11450 Authors demonstrated that a flag-tagged QKI::NTRK2 (e6::e16) fusion was able to transform Ink4a−/−/Arf−/− astrocytes, and these cells induced astrocytomas when injected intracranially into mice. QKI… (full text at CIViC) PMID 27402815 · Ni et al., 2017 · Open in CIViC	civic
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	2	accepted	EID11451 Authors demonstrated that a flag-tagged QKI::NTRK2 (e6::e16) fusion was able to transform Ink4a−/−/Arf−/− astrocytes, and these cells induced astrocytomas when injected intracranially into mice. Thi… (full text at CIViC) PMID 27402815 · Ni et al., 2017 · Open in CIViC	civic